drugset / Trial / NCT01973504

Phase 2c Dose Comparison Study of MP4OX in Trauma

NCT01973504 ↗

Phase 2 Withdrawn Sangart
RandomizedParallel-groupQuadruple-blindTreatment

Summary

MP4OX is being developed as an ischemic rescue therapy to perfuse and oxygenate tissues at risk during hemorrhagic shock. MP4OX is a pegylated hemoglobin-based colloid designed to improve perfusion and target delivery of oxygen to ischemic tissues. This study will evaluate safety and efficacy of MP4OX treatment, in addition to standard therapy, in trauma patients suffering from lactic acidosis due to severe hemorrhagic shock.

Timeline

Start
2013-12
Primary completion
2015-12
Completion
2016-03

Outcome

Outcome not reported

Stopped: “Sangart ceased operations”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MP4OX Protein / enzyme biologic 500 ml —
Subject MP4OX Protein / enzyme biologic 750 ml —

Indications